Ian Read

Executive Chairman at Population Health Investment Co., Inc.

Ian Read

Ian Read

Executive Chairman at Population Health Investment Co., Inc.

Overview
Career Highlights

Pfizer SA de CV
Zoetis, Inc.
International Federation of Pharmaceutical Manufacturers

RelSci Relationships

5637

Number of Boards

21

Birthday

1953

Age

68

Number of Awards

4

Relationships
RelSci Relationships are individuals Ian Read likely has professional access to. A relationship does not necessarily indicate a personal connection.

Chief Executive Officer at Pfizer, Inc.

Relationship likelihood: Strong

Co-Founder at Granite Broadcasting Corporation

Relationship likelihood: Strong

Co-Founder at Fieldpoint Private Bank & Trust

Relationship likelihood: Strong

Global Chair at Gerson Lehrman Group, Inc.

Relationship likelihood: Strong

Chief Executive Officer at Rempex Pharmaceuticals, Inc.

Relationship likelihood: Strong

President & Chief Executive Officer at X-Vax Technology, Inc.

Relationship likelihood: Strong

Chief Executive Officer at Rabin Martin

Relationship likelihood: Strong

Group President, Chief Business Officer at Pfizer, Inc.

Relationship likelihood: Strong

President & Chief Executive Officer at United States Council for International Business

Relationship likelihood: Strong

Former Group President, North American Consumer Products at Kimberly-Clark Corp.

Relationship likelihood: Strong

Paths to Ian Read
Potential Connections via
Relationship Science
You
Ian Read
Executive Chairman at Population Health Investment Co., Inc.
Education
B.Sc. in Chemical Engineering
Class of 1974

Imperial College London (officially The Imperial College of Science, Technology and Medicine) is a public research university located in London, England, specialising in science, engineering, medicine and business. A former constituent college of the federal University of London, it became fully independent on 9 July 2007, as part of the celebrations of its centenary.

Memberships
Member
Prior

The Business Council is a voluntary association of business leaders whose members meet several times a year for the free exchange of ideas both among themselves and with thought leaders from many sectors. In its most fundamental form, the Council seeks to foster understanding through discussion. It promotes learning, best practice sharing and networking by its members with a view to making a contribution to our society, the global economy and to business generally. Since its founding more than 75 years ago, The Business Council membership has consisted of a group of current or former chief executive officers from a broad range of companies. All major industries are represented among the members of The Business Council. Because schedule demands on senior business executives are extensive, the Council provides an especially valuable opportunity to discuss major subjects in a broader ranging forum than is normally available in the course of business activities. As part of its process, the Council invites leaders in government, politics, academia, science, medicine, technology and other sectors to address the Council and to participate in its discussions. Council members hope that these discussions result in better understanding by their invited guests as well as by the members themselves. Today, the Council meets three times a year in a collegial atmosphere to share and explore ideas.As a gathering of peers from many fields, the Council is entirely an educational and deliberative forum. It never takes positions as an organization and does not advocate any policy or course of action. Individual members sometimes do present their own views in public discussions. But they do so as individuals, rather than as representatives of the Council.

Career History
Executive Chairman
2020 - Current

Population Health Investment Co., Inc. operates as a blank check company with the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase and reorganization or similar business combination with one or more businesses. The company was founded by Clive A. Meanwell and Ian C. Read on September 11, 2020 and is headquartered in New York, NY.

Operating Executive for Global Healthcare
2020 - Current

The Carlyle Group is a global alternative asset manager with more than $157 billion in assets under management across 101 funds and 64 fund of funds vehicles. Founded in 1987 in Washington, DC, Carlyle has grown into one of the world’s largest and most successful investment firms, with more than 1,300 professionals operating in 32 offices in North America, South America, Europe, the Middle East, North Africa, Sub-Saharan Africa, Japan, Asia and Australia.

Chief Executive Officer
Tenure Unconfirmed
Boards & Committees
Member, Board of Trustees
Prior

The Healthcare Leadership Council (HLC), a coalition of chief executives from all disciplines within American healthcare, is the exclusive forum for the nation’s healthcare leaders to jointly develop policies, plans, and programs to achieve their vision of a 21st century system that makes affordable, high-quality care accessible to all Americans.

Director
Prior

The European Federation of Pharmaceutical Industries and Associations (EFPIA) is a Brussels-based trade association founded in 1978 representing the research-based pharmaceutical industry operating in Europe.

Board Member
Tenure Unconfirmed

Over the last five years, the Pfizer Foundation and Pfizer Worldwide Philanthropy department has developed platform focused on investing the full range of the company's resources — people, skills, expertise and funding — to broaden access to medicines and strengthen healthcare delivery for underserved people around the world. The new philanthropy platform, Pfizer Investments in Health, offers a more coordinated approach to contribute to society beyond medicines, centered around developing stronger relationships with their partners (grantees, field experts, etc.) and including cash grants, capacity building/technical assistance, product, skilled volunteers and stronger networking. This has resulted in mutual benefits for Pfizer and for its philanthropic partners. Introduction The Pfizer Foundation, the philanthropic arm of the world-leading pharmaceutical company, Pfizer Inc, is committed to addressing global health needs through community programs that also leverage its corporate resources and connections. Pfizer had successfully implemented international and smaller scale domestic HIV/AIDS programs, but recognized the need for greater national attention. In 2002, the Pfizer Foundation developed the Southern HIV/AIDS Prevention Initiative (SHAPI) in reaction to the growing HIV/AIDS epidemic in the southern United States. HIV/AIDS rates were still alarmingly high and growing, especially in the U.S. South. SHAPI, a three-year program from 2003 to 2006, provided more than $3 million in program investments and $3 million in capacity-building opportunities. To further develop the program and assist in its strategic planning and implementation the Foundation engaged TCC Group in 2002. Developing Focus and Goals In response to TCC Group's research and facilitated discussions with stakeholders, the Pfizer Foundation focused SHAPI on prevention programs in small to mid-size AIDS Service Organizations (ASOs), particularly those working with minorities and women. With TCC's help, the Foundation developed a clear set of goals for SHAPI. The core strategy focused on building relationships and supporting a targeted number of organizations, and included investments focused on direct services in local prevention and education programs and additional investments designed to create longer lasting impact through organizational capacity building and regional networking opportunities. Together, TCC and the Pfizer Foundation selected 23 grantees and 39 additional finalists. Grantees were provided annual grants of up to $50,000 for prevention programs, and all grantees and finalists were provided with opportunities to improve organizational effectiveness and be a part of the SHAPI network. TCC managed the overall initiative and worked closely with grantees to achieve the SHAPI goals of capacity building and networking. Opportunities Beyond the Grants In order to offer grantees tailored capacity building opportunities, TCC Group developed a new, comprehensive assessment tool for nonprofit organizations that was based on best practices in the field and tested by leading ASOs (now further developed, available on-line and called the Core Capacity Assessment Tool (CCAT)). Using the CCAT, TCC identified target areas for capacity building in each participating organization as well as cross-cutting needs for clusters of organizations. Each SHAPI grantee was offered annual customized capacity building recommendations and funding support (which often was nearly equal to their program grant) as well as general opportunities, such as board development, peer mentoring, software and technology training, financial management, and evaluation technical assistance. In addition, TCC worked with the Foundation to provide networking opportunities to the SHAPI grantees and finalists, such as training sessions, teleconferences, and peer exchange. In particular, the Pfizer Foundation sponsored its SHAPI partners to attend the annual United States Conference on AIDS and hosted its own annual HIV/AIDS prevention conferences focused on HIV/AIDS prevention and capacity building needs identified throughout the year. During these networking opportunities, the Pfizer Foundation invited and introduced Pfizer Inc's HIV Community Liaisons (HCLs) to SHAPI partners to be able to foster more localized relationships with Pfizer Inc and to provide access to Pfizer Inc's local resources, such as training materials, mini-grants/sponsorships and volunteers. Through these networking opportunities, grantees and finalists shared ideas, information, and inspiration. "Long after Pfizer's funding relationship with [us] has concluded, the skills and expertise culled from these capacity-building efforts will continue to make [us] a trusted and well-respected organization." – NC Grantee

Political Donations
$50K
2017

Partner at Solamere Capital LLC

$208
2016
$208
2015
Public Holdings
Restricted data only for RelSci Professional users.
Awards & Honors
Rank #233
2014
Chief Executive Magazine - Wealth Creators
Rank #75
2013
Crain's New York Business Magazine - New York Area's Fortunate 100
Rank #20
2012
Crain's New York Business Magazine - New York Area's Fortunate 100
This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Ian Read. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Ian Read's profile does not indicate a business or promotional relationship of any kind between RelSci and Ian Read.